Skip to main content
Premium Trial:

Request an Annual Quote

Enzo Biochem's Q1 2010 Revenues Jump 19 Percent

NEW YORK (GenomeWeb News) – Enzo Biochem reported after the close of the market Thursday that its first-quarter 2010 revenues increased 19 percent, led by a 36 percent jump in revenues for its Enzo Clinical Labs division.

The New York-based firm brought in total revenues of $25.2 million for the three-month period ended Oct. 31, 2009, compared to $21.1 million for the first quarter of 2009. Revenues for its Enzo Life Sciences division increased around 16 percent, with product revenues increasing to $10.7 million from $10 million year over year, and royalty and license fees increasing to $3.3 million from $2.9 million.

Assay Designs, a reagent kit maker that Enzo acquired earlier this year for around $12.2 million, contributed revenues of $2.7 million for the quarter.

Enzo Clinical Labs had revenues of $11.1 million for the quarter, up from $8.2 million in the comparable period of fiscal 2009.

Enzo Biochem's net loss dropped sharply to $1.8 million, or $.03 per share, from $6.4 million, or $.16 per share.

The firm finished the quarter with $46.4 million in cash, cash equivalents, and short-term investments.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.